Last updated 10 days ago

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

10000 patients around the world

Available in Puerto Rico, Brazil, Argentina, Mexico

Eli Lilly and Company

145Research sites

10000Patients around the world

This study is for people with

Obesity

Renal disease

Renal Insufficiency

From 45 Years

All Gender

: A body mass index of ≥27.0 kilograms per meter squared (kg/m^2).
Participants may be with or without type 2 diabetes (T2D) unless their hemoglobin A1c (HbA1c) is 10% or lower.
Participants have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), as evidenced at least one of the following:
Coronary artery disease.
Cerebrovascular disease.
Peripheral arterial disease.
Chronic kidney disease defined as:
eGFR <45 millilitres/minute/1.73 meter squared (mL/min/1.73m^2) and UACR >30 milligram/gram (mg/g).
eGFR <60 mL/min/1.73 m^2 and UACR >100 mg/g, or.
eGFR <75 mL/min/1.73 m^2 and UACR >300 mg/g (eGFR is calculated based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin c equation as determined by central lab).

: Participants have type 1 diabetes or history of diabetic ketoacidosis.
Participants have any of the following cardiovascular conditions ≤ 90 days prior to randomization:
Myocardial infarction.
Acute coronary syndrome.
Stroke, or.
Coronary, peripheral, or carotid artery arterial revascularization procedure.
Have acute decompensated heart failure requiring hospitalization.
Have New York Heart Association (NYHA) Classification Class IV heart failure at screening.
Participants have an eGFR <20 mL/min/1.73 m^2 at screening.
Have UACR >5000 mg/g at screening.
Have received any form of dialysis ≤ 90 days from the date of randomization.
Have either undergone a kidney transplant or have a transplant procedure scheduled.
Participants have had or plan to have a surgical treatment for obesity.
Have a history of chronic or acute pancreatitis.
Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2.
Have a known clinically significant gastric emptying abnormality, such as severe gastroparesis or gastric outlet obstruction.